Önlen, YusufBal, TayibeÇabalak, MehmetÖztoprak, Nefise ÇuvalcıSarı, Nagehan DidemKurtaran, BehiceŞenateş, Ebubekir2023-07-262023-07-2620221300-4948https://doi.org/10.5152/tjg.2022.21271https://search.trdizin.gov.tr/yayin/detay/1134402https://hdl.handle.net/20.500.12684/12470Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (?65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults. Copyright @ Author(s)en10.5152/tjg.2022.21271info:eu-repo/semantics/openAccessAgechronic hepatitis Cdirect-acting antiviral agentselderlyTurkeyantivirus agentdasabuvir plus ombitasvir plus paritaprevir plus ritonavirledipasvir plus sofosbuvirribavirinsofosbuvirantivirus agentribavirinsofosbuviradultagedanemiaangioneurotic edemaArticlebleedingchronic hepatitis Ccohort analysisconstipationdecompensated liver cirrhosisdemographydrug efficacydrug safetydrug withdrawaldyspneafatiguefemalegroups by ageheadacheHepatitis C virus genotype 1humanhyperbilirubinemiainsomnialiver cell carcinomaliver cirrhosismajor clinical studymalemedical historymiddle agedmulticenter studynauseanonhumanobservational studypopulation researchprospective studyprurituspsychosissex differencesustained virologic responseTurkey (republic)urticariayoung adultchronic hepatitis Cclinical trialcombination drug therapygeneticsHepacivirustreatment outcometurkey (bird)AdultAgedAntiviral AgentsDrug Therapy, CombinationHepacivirusHepatitis C, ChronicHumansMaleProspective StudiesRibavirinSofosbuvirSustained Virologic ResponseTreatment OutcomeTurkeyArticle33108628731134402359468962-s2.0-85139571415WOS:000955590200007Q3Q4